Morgan Stanley raised the price target for the Haemonetics Corporation (NYSE:HAE) stock from “an Overweight” to “an Equal-weight”. The rating was released on April 20, 2021. The research report from Barrington Research has upgraded the stock from Mkt Perform to Outperform, with a price target set at $140. In their research brief published November 05, 2020, Barrington Research analysts upgraded the Haemonetics Corporation stock from Mkt Perform to Outperform with a price target of $106.
Historical Earnings Surprises and Revenue Forecasts
Profit is the most critical financial performance measure. Every investor in a business is looking forward to the earnings report as stock price to increase when earnings exceed market expectations and progressively decrease when earnings do not meet expectations. The firm reported an earnings per share (EPS) of $0.81 during the last quarter as opposed to a consensus estimate of $0.65, which indicates the company beat its estimate by $0.16, which implies that the company surprised the market by 24.60%. It appears that the average earnings per share estimate for the current quarter (ending in Mar 2021) is $0.69. This is an average of 7 analysts’ earnings, where the high earnings per share estimate is $0.76 and the low earnings per share estimate is $0.6. According to 6 analyst estimates, an average revenue estimate of $222.98M is projected for the current quarter with a high revenue estimate of $231.28M and a low estimate of $217M.
The latest trade, Performances and Moving Averages give us the following Picture
The share price of Haemonetics Corporation (NYSE:HAE) dipped -10.70% to close Tuesday’s market session at $66.69, lower as compared to yesterday’s close. The stock price fluctuated between $66.465 and $71.7394 throughout the trading session with the volume trading being 5933179 shares, which represented a significant variation when compared to the three months average volume of 514.60K shares. The firm’s stock price fluctuated -43.27% within the last five trades and -41.47% within the last 30 trades, which was a significant change from the beginning of this year. Despite the fact that the share price decreased -28.89% in the last 6 months and -48.01% was subtracted to its value over the previous 3 months. HAE stock is trading at a margin of -41.06%, -44.98% and -37.34% apart from the 20-Day, 50-Day and 200-Day Simple Moving Average prices.
As of the close of trading, HAE deals in the Healthcare domain. The stock is trading -53.07 percent below its 52-week high and -10.00 percent above its 52-week low. For example, looking both at the price and the high and low measurements of 52 weeks will give you a clearer picture of the direction the price is heading. The firm’s Weighted Alpha is -24.2. A positive weighted alpha indicates the firm has done well over the course of the year, whereas one below 0 indicates that the firm has done poorly.
What Does Haemonetics Corporation’s Profitability and Valuation Ratios Tell Us About the Stock?
With regard to the profitability of the company, the operating margin is currently at 15.50 percent and the profit margin is 12.20 percent, and the company has reported a gross margin of 48.60 percent. The profit margin, also known as the revenue ratio or gross profit ratio, is an efficiency figure used to estimate the business’s profitability by comparing net income and sales. The higher the number, the more profits are generated for the company and vice versa.
The stock’s market cap achieved a total value of $3.44 billion as of the last trading session. Market capitalization is the total value of all outstanding shares of a corporation and it is used to measure a company’s market value. The price-to-earnings ratio for Haemonetics Corporation (NYSE:HAE) is 31.59. The price-to-earnings ratio is a method of assessing corporate values by comparing them to their per-share profit. Forward P/E stands at 18.21. Forward price-to-earnings is calculated using predicted earnings for the next financial year’s P/E determination. The stock has achieved an effective Price-to-Sales Ratio of 3.89 that mirrors the cost to be found for sales by the market. The firm managed a Price-to-Book ratio of 4.71, which equates the market value of a stock with its book value.
Is Insider Trading a Real Thing?
Almost all investors and traders prefer to invest in shares controlled by the management of a corporation as a management company will be more likely to run the business itself and to never conduct things against the management’s desires and will always try to do what is best for their shareholders. Currently, 0.50 percent of Haemonetics Corporation shares are owned by insiders, and 98.50 percent are held by financial institutions. Lingamneni Anila, the EVP, Chief Technology Officer at Haemonetics Corporation (HAE) has sold 170 shares of firm on Apr 16 at a price of $119.44 against the total amount of $20305.0. In another inside trade, Scanlan Jacqueline, SVP, Global Human Resources of Haemonetics Corporation (NYSE:HAE) sold 107 shares of the firm on Mar 08 for a total worth of $12847.0 at a price of $120.07. An inside trade which took place on Mar 08, EVP and General Counsel of Haemonetics Corporation Basil Michelle L sold 385 shares of firm against total price of $46227.0 at the cost of $120.07 per share.